Abstract
Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m2) - the monoclonal antibody to B-cell antigen CD20 - in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p
Original language | English |
---|---|
Pages (from-to) | 923-924 |
Number of pages | 2 |
Journal | Lancet |
Volume | 360 |
Issue number | 9337 |
DOIs | |
Publication status | Published - Sep 21 2002 |
ASJC Scopus subject areas
- Medicine(all)